Transforming growth factor beta receptor 1 (TGFBR1) (TGFBR1)

Transforming growth factor beta receptor 1 (TGFBR1), also known as ALK5, is a transmembrane serine/threonine kinase that serves as a pivotal component of the TGF-beta signaling pathway (UniProt: P36897). The mRNA of TGFBR1 encodes the protein that, upon activation by TGF-beta ligands and the type II receptor, phosphorylates SMAD2 and SMAD3 to regulate genes involved in cell cycle control, apoptosis, and extracellular matrix remodeling (NCBI Gene: 7046). In disease states, overactive TGFBR1 signaling is a primary driver of tissue fibrosis and promotes tumor metastasis by inducing epithelial-mesenchymal transition (EMT) and immune evasion (PubMed: 28249128). Targeting the TGFBR1 mRNA specifically, rather than the protein, allows for the use of RNA-based therapeutics like antisense oligonucleotides or siRNA to knockdown receptor expression at the pre-translational level (PubMed: 24743964). This approach is being explored to treat fibrotic disorders and various cancers where TGF-beta signaling is pathologically elevated. However, therapeutic intervention must carefully manage potential side effects, such as cardiotoxicity and the development of skin lesions, which have been observed with systemic TGF-beta pathway inhibition (PubMed: 25135958).

Other names

ALK5Activin receptor-like kinase 5TGF-beta receptor type ITbetaR-ISKR4ACVRLK4

Inhibition of TGF-beta signaling by either degrading the TGFBR1 mRNA transcript via antisense oligonucleotides or RNA interference to prevent protein synthesis, or by competitively inhibiting the ATP-binding site of the TGFBR1 kinase domain to prevent downstream SMAD phosphorylation.